HAND SANITIZER- alcohol hand sanitizer gel United States - English - NLM (National Library of Medicine)

hand sanitizer- alcohol hand sanitizer gel

ningbo lanzi cosmetic technology co., ltd - alcohol (unii: 3k9958v90m) (alcohol - unii:3k9958v90m) - antiseptic for hand sanitizing to reduce bacteria on the skin. do not inhale or ingest. stop use and ask a doctor if irritation or rash appears or lasts.

CLOPIDOGREL BISULFATE- clopidogrel tablet, film coated United States - English - NLM (National Library of Medicine)

clopidogrel bisulfate- clopidogrel tablet, film coated

mylan pharmaceuticals inc. - clopidogrel bisulfate (unii: 08i79htp27) (clopidogrel - unii:a74586sno7) - clopidogrel 75 mg - in patients with established peripheral arterial disease or with a history of recent myocardial infarction (mi) or recent stroke clopidogrel tablets are indicated to reduce the rate of mi and stroke. clopidogrel tablets are contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. clopidogrel tablets are contraindicated in patients with hypersensitivity (e.g., anaphylaxis) to clopidogrel or any component of the product [see adverse reactions (6.2)] . available data from cases reported in published literature and postmarketing surveillance with clopidogrel use in pregnant women have not identified any drug-associated risks for major birth defects or miscarriage [see data] . there are risks to the pregnant woman and fetus associated with myocardial infarction and stroke [see clinical considerations] . no evidence of fetotoxicity was observed when clopidogrel was administered to pregnant rats and rabbits during organogenesis at doses corresponding to 65 and 78

TRAZODONE HYDROCHLORIDE tablet, film coated United States - English - NLM (National Library of Medicine)

trazodone hydrochloride tablet, film coated

apotheca inc. - trazodone hydrochloride (unii: 6e8zo8lrnm) (trazodone - unii:ybk48bxk30) - trazodone hydrochloride 50 mg - trazodone hydrochloride tablets usp are indicated for the treatment of major depressive disorder (mdd) in adults. the efficacy of trazodone hydrochloride tablets has been established in trials with the immediate release formulation of trazodone [see clinical studies (14) ] . none. pregnancy category c trazodone hydrochloride has been shown to cause increased fetal resorption and other adverse effects on the fetus in two studies using the rat when given at dose levels approximately 30 to 50 times the proposed maximum human dose. there was also an increase in congenital anomalies in one of three rabbit studies at approximately 15 to 50 times the maximum human dose. there are no adequate and well-controlled studies in pregnant women. trazodone hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. trazodone and/or its metabolites have been found in the milk of lactating rats, suggesting that the drug may

FLUOXETINE tablet, film coated United States - English - NLM (National Library of Medicine)

fluoxetine tablet, film coated

dr.reddy's laboratories limited - fluoxetine hydrochloride (unii: i9w7n6b1kj) (fluoxetine - unii:01k63sup8d) - fluoxetine 10 mg - fluoxetine tablets are indicated for the acute and maintenance treatment of major depressive disorder in adult patients and in pediatric patients aged 8 to18 years [see clinical studies (14.1) ].   the usefulness of the drug in adult and pediatric patients receiving fluoxetine for extended periods should periodically be re-evaluated [see dosage and administration (2.1) ].   fluoxetine tablets are indicated for the acute and maintenance treatment of obsessions and compulsions in adult patients and in pediatric patients aged 7 to 17 years with obsessive compulsive disorder (ocd) [see clinical studies (14.2) ].   the effectiveness of fluoxetine tablets in long-term use, i.e., for more than 13 weeks, has not been systematically evaluated in placebo-controlled trials. therefore, the physician who elects to use fluoxetine tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see dosage and administration (2.2) ]. fluoxetine tablets are indicate

PRIMIDONE tablet United States - English - NLM (National Library of Medicine)

primidone tablet

dr. reddy's laboratories limited - primidone (unii: 13afd7670q) (primidone - unii:13afd7670q) - primidone 50 mg - primidone tablets, used alone or concomitantly with other anticonvulsants, are indicated in the control of grand mal, psychomotor, and focal epileptic seizures. it may control grand mal seizures refractory to other anticonvulsant therapy. primidone tablet is contraindicated in:  1) patients with porphyria and  2) patients who are hypersensitive to phenobarbital (see clinicalpharmacology ).

sotret- isotretinoin capsule, gelatin coated
sotret- isotretinoin capsule, liquid filled United States - English - NLM (National Library of Medicine)

sotret- isotretinoin capsule, gelatin coated sotret- isotretinoin capsule, liquid filled

ranbaxy laboratories inc. - isotretinoin (unii: eh28up18if) (isotretinoin - unii:eh28up18if) - capsule, gelatin coated - 10 mg - sotret is indicated for the treatment of severe recalcitrant nodular acne. nodules are inflammatory lesions with a diameter of 5 mm or greater. the nodules may become suppurative or hemorrhagic. “severe,” by definition,2 means “many” as opposed to “few or several” nodules. because of significant adverse effects associated with its use, sotret should be reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. in addition, sotret is indicated only for those female patients who are not pregnant, because sotret can cause severe birth defects (see boxed contraindications and warnings ). a single course of therapy for 15 to 20 weeks has been shown to result in complete and prolonged remission of disease in many patients.1,3,4 if a second course of therapy is needed, it should not be initiated until at least 8 weeks after completion of the first course, because experience has shown that patients may continue to improve while off isotretinoin caps

CITALOPRAM HYDROBROMIDE tablet, film coated United States - English - NLM (National Library of Medicine)

citalopram hydrobromide tablet, film coated

dr. reddy's laboratories limited - citalopram hydrobromide (unii: i1e9d14f36) (citalopram - unii:0dhu5b8d6v) - citalopram 10 mg - citalopram tablets are indicated for the treatment of major depressive disorder (mdd) in adults [see clinical studies ( 14)] . citalopram tablets are contraindicated in patients: - taking, or within 14 days of stopping, maois (including maois such as linezolid or intravenous methylene blue) because of an increased risk of serotonin syndrome [see warnings and precautions ( 5.3), drug interactions ( 7)]. - taking pimozide because of risk of qt prolongation [see drug interactions ( 7)] . - with known hypersensitivity to citalopram or any of the inactive ingredients in citalopram tablets. reactions have included angioedema and anaphylaxis [see adverse reactions ( 6.2)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antidepressants during pregnancy. healhcare providers are encouraged to register patients by calling the national pregnancy registry for antidepressants at 1-844-405-6185 or visiting online at https://womensmentalhealth.org/resea

VENLAFAXINE HYDROCHLORIDE capsule, extended release United States - English - NLM (National Library of Medicine)

venlafaxine hydrochloride capsule, extended release

dr.reddy's laboratories ltd. - venlafaxine hydrochloride (unii: 7d7rx5a8mo) (venlafaxine - unii:grz5rcb1qg) - venlafaxine 37.5 mg - venlafaxine hydrochloride extended-release capsules are indicated for the treatment of major depressive disorder (mdd). efficacy was established in three short-term (4, 8, and 12 weeks) and two long-term, maintenance trials. venlafaxine hydrochloride extended-release capsules are indicated for the treatment of generalized anxiety disorder (gad). efficacy was established in two 8-week and two 26-week placebo-controlled trials. venlafaxine hydrochloride extended-release capsules are indicated for the treatment of social anxiety disorder (sad), also known as social phobia. efficacy was established in four 12-week and one 26-week, placebo-controlled trials.   venlafaxine hydrochloride extended-release capsules are indicated for the treatment of panic disorder (pd), with or without agoraphobia. efficacy was established in two 12-week placebo-controlled trials. hypersensitivity to venlafaxine hydrochloride, desvenlafaxine succinate or to any excipients in the formulation the use of maois (intended to treat psychiat

KAZANO- alogliptin and metformin hydrochloride tablet, film coated United States - English - NLM (National Library of Medicine)

kazano- alogliptin and metformin hydrochloride tablet, film coated

takeda pharmaceuticals america, inc. - alogliptin benzoate (unii: een99869sc) (alogliptin - unii:jhc049lo86), metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - alogliptin 12.5 mg - kazano is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. limitations of use kazano is not recommended for use in patients with type 1 diabetes mellitus. kazano is contraindicated in patients with: - severe renal impairment (egfr below 30 ml/min/1.73 m2 ) [see warnings and precautions (5.1)] . - acute or chronic metabolic acidosis, including diabetic ketoacidosis with or without coma. - history of serious hypersensitivity reaction to alogliptin or metformin or any of the excipients in kazano, such as anaphylaxis, angioedema and severe cutaneous adverse reactions [see warnings and precautions (5.4), adverse reactions (6.2)]. risk summary limited available data with kazano or alogliptin in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. published studies with metformin use during pregnancy have not reported a clear association with metformin and major birth defect or miscarriage risk [se

BRINTELLIX- vortioxetine tablet, film coated United States - English - NLM (National Library of Medicine)

brintellix- vortioxetine tablet, film coated

takeda pharmaceuticals america, inc. - vortioxetine hydrobromide (unii: tks641koay) (vortioxetine - unii:3o2k1s3wqv) - vortioxetine 5 mg - brintellix is indicated for the treatment of major depressive disorder (mdd). the efficacy of brintellix was established in six 6 to 8 week studies (including one study in the elderly) and one maintenance study in adults [see clinical studies (14)] . pregnancy category c risk summary there are no adequate and well-controlled studies of brintellix in pregnant women. vortioxetine caused developmental delays when administered during pregnancy to rats and rabbits at doses 15 and 10 times the maximum recommended human dose (mrhd) of 20 mg, respectively. developmental delays were also seen after birth in rats at doses 20 times the mrhd of vortioxetine given during pregnancy and through lactation. there were no teratogenic effects in rats or rabbits at doses up to 77 and 58 times, the mrhd of vortioxetine, respectively, given during organogenesis. the incidence of malformations in human pregnancies has not been established for brintellix. all human pregnancies, regardless of drug exposure, have a background rate of